Literature DB >> 35991721

Dermatomal rash after Shingrix vaccination: cause or coincidence?

Nitish Mittal1, Nikita Dhir2, Neha Mittal3.   

Abstract

Dermatological reactions have been reported following Shingrix vaccine administration in previous published cases, but dermatomal rash after Shingrix vaccination has not been reported in the United States. This case describes a 73-year-old immunocompetent woman with a dermatomal rash after Shingrix recombinant vaccine administration. This case highlights the rare possibility of an acute reaction after Shingrix vaccine administration, which should be recognized. Nonetheless, the vaccine has been shown to be very effective at preventing varicella zoster virus reactivation and postherpetic neuralgia, so the benefit of receiving the vaccination significantly outweighs the risk.
Copyright © 2022 Baylor University Medical Center.

Entities:  

Keywords:  Dermatomal rash; Shingrix; herpes zoster; vaccine

Year:  2022        PMID: 35991721      PMCID: PMC9373764          DOI: 10.1080/08998280.2022.2071118

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  14 in total

Review 1.  Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine.

Authors:  Thomas C Heineman; Anthony Cunningham; Myron Levin
Journal:  Curr Opin Immunol       Date:  2019-04-17       Impact factor: 7.486

2.  Vaccine-derived varicella zoster infection in a kidney transplant recipient after zoster vaccine live administration.

Authors:  Edgar Ortiz-Brizuela; Francisco Leal-Vega; Jennifer Cuellar-Rodríguez; Miriam Bobadilla-Del-Valle; Alfredo Ponce-de-León
Journal:  Vaccine       Date:  2019-05-17       Impact factor: 3.641

Review 3.  Blistering autoimmune skin reaction following SHINGRIX vaccination in an ulcerative colitis patient: Case report and literature review.

Authors:  Harrison Bell; Natasha Kamal; Uni Wong
Journal:  Vaccine       Date:  2020-10-13       Impact factor: 3.641

Review 4.  Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.

Authors:  Nicolas Lecrenier; Pierre Beukelaers; Romulo Colindres; Desmond Curran; Carine De Kesel; Jean-Philippe De Saegher; Arnaud M Didierlaurent; Edouard Y Ledent; Johann F Mols; Tomas Mrkvan; Marie Normand-Bayle; Lidia Oostvogels; Fernanda Tavares Da Silva; Ventzislav Vassilev; Carlota Vinals; Alain Brecx
Journal:  Expert Rev Vaccines       Date:  2018-07-20       Impact factor: 5.217

5.  [Zoster disease after Shingrix vaccination].

Authors:  D Kohn; T Wetzig
Journal:  Hautarzt       Date:  2020-12-08       Impact factor: 0.751

6.  Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.

Authors:  Alemnew F Dagnew; Osman Ilhan; Won-Sik Lee; Dariusz Woszczyk; Jae-Yong Kwak; Stella Bowcock; Sang Kyun Sohn; Gabriela Rodriguez Macías; Tzeon-Jye Chiou; Dimas Quiel; Mickael Aoun; Maria Belen Navarro Matilla; Javier de la Serna; Samuel Milliken; John Murphy; Shelly A McNeil; Bruno Salaun; Emmanuel Di Paolo; Laura Campora; Marta López-Fauqued; Mohamed El Idrissi; Anne Schuind; Thomas C Heineman; Peter Van den Steen; Lidia Oostvogels
Journal:  Lancet Infect Dis       Date:  2019-08-06       Impact factor: 25.071

7.  Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Authors:  Anthony L Cunningham; Himal Lal; Martina Kovac; Roman Chlibek; Shinn-Jang Hwang; Javier Díez-Domingo; Olivier Godeaux; Myron J Levin; Janet E McElhaney; Joan Puig-Barberà; Carline Vanden Abeele; Timo Vesikari; Daisuke Watanabe; Toufik Zahaf; Anitta Ahonen; Eugene Athan; Jose F Barba-Gomez; Laura Campora; Ferdinandus de Looze; H Jackson Downey; Wayne Ghesquiere; Iris Gorfinkel; Tiina Korhonen; Edward Leung; Shelly A McNeil; Lidia Oostvogels; Lars Rombo; Jan Smetana; Lily Weckx; Wilfred Yeo; Thomas C Heineman
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

8.  Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.

Authors:  Kathleen L Dooling; Angela Guo; Manisha Patel; Grace M Lee; Kelly Moore; Edward A Belongia; Rafael Harpaz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-26       Impact factor: 17.586

9.  Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.

Authors:  Tino F Schwarz; Naresh Aggarwal; Beate Moeckesch; Isabelle Schenkenberger; Carine Claeys; Martine Douha; Olivier Godeaux; Katrijn Grupping; Thomas C Heineman; Marta Lopez Fauqued; Lidia Oostvogels; Peter Van den Steen; Himal Lal
Journal:  J Infect Dis       Date:  2017-12-12       Impact factor: 5.226

10.  Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.

Authors:  Tara C Anderson; Nina B Masters; Angela Guo; Leah Shepersky; Andrew J Leidner; Grace M Lee; Camille N Kotton; Kathleen L Dooling
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2022-01-21       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.